Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin'...(teen patients died 7 due to treatmentrel...),Health
teen patients died, 7 due to treatment related toxicities, and 6 due to progressive disease. The estimated 3 year event free survival (EFS) 64%.
"These three additional studies add to the growing body of clinical trial evidence that radio-immunotherapy with Zevalin produces high, durable rates of complete remission in high risk, relapsed or refractory NHL," noted Jack Singer, M.D. and Chief Medical Officer of CTI. "We believe that the impressive 73% CR rate when given as a single agent in previously untreated patients with follicular NHL is worth pursuing in additional trials as it could potentially provide an alternative to multiagent chemotherapy regimens particularly among elderly or infirm patients. Similarly, the 100% CR rate in MALT is an intriguing finding that could represent an additional registration route as it is an unmet medical need. We believe with these and additional prospective randomized clinical trials Zevalin, Radio-Immunotherapy, may finally assume a role alongside cornerstone treatment regimens for NHL," Dr. Singer added.
About Zevalin(R)
Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non- Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naïve, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.
Rare deaths associated with an infusion reaction symptom complex have
occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90
Zevalin administration results in severe and prolonged cytopeni
'/>"/>
| SOURCE Cell Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products
2. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
3. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
4. Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations
5. La Rabida Children's Hospital to Host Three-Day Course on Gait Treatment Options for Children with Cerebral Palsy
6. Three Chef-Dietitians Win CanolaInfo Recipe Contest
7. Three Chicago Area Fertility Agencies Launch Shared Risk Program
8. Innerscope Research Strengthens Management Team With Three Executive Appointments
9. Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obamas First Term
10. New Jersey Jury Awards $12.9 Million to Three Patients Whose Use of Roche Acne Medication Accutane Found to Cause Severe Bowel Illness
11. Three Community Leaders to Receive Foundations 2008 California Peace Prize
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |